Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KID in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT05199311Phase 2Suspended
- Sponsor
- Hackensack Meridian Health
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (4 arms), sponsored by Hackensack Meridian Health. Primary endpoints: Rate of treatment emergent adverse events at 16 weeks and Complete Response and stringent Complete Response at 16 weeks. Started May 2022; status: suspended.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05199311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199311.